Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pediatric Exclusivity For ‘Deemed’ Biologics Needs Clarity, Industry Tells US FDA

Feb 21 2019

• By Sue Sutter

Transition sign

Related Content

FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear

May 23 2016

BLAs More Appealing As 'Transition' NDAs, ANDAs Set To Lose Exclusivity

Mar 21 2016

US FDA's Gottlieb Shuts The Door On Exclusivity For 'Transition' Biologics

Dec 11 2018

When Drugs Become Biologics: US FDA Guidances Explain 'Transition Provisions'

Dec 11 2018

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

Boehringer Ingelheim GmbH

Additional Topics

United States Biosimilars Biologics Regulation BioPharmaceutical Metabolic Disorders

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window